ES2064130T3 - Utilizacion de droloxifeno para el tratamiento de enfermedades de los huesos. - Google Patents

Utilizacion de droloxifeno para el tratamiento de enfermedades de los huesos.

Info

Publication number
ES2064130T3
ES2064130T3 ES92105595T ES92105595T ES2064130T3 ES 2064130 T3 ES2064130 T3 ES 2064130T3 ES 92105595 T ES92105595 T ES 92105595T ES 92105595 T ES92105595 T ES 92105595T ES 2064130 T3 ES2064130 T3 ES 2064130T3
Authority
ES
Spain
Prior art keywords
diseases
droloxifeno
bones
treatment
droloxifene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92105595T
Other languages
English (en)
Inventor
Kazuaki Niikura
Yoshimitsu Nakajima
Yoshitada Notsu
Ryuji Ono
Osamu Nakayama
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astellas Deutschland GmbH
Original Assignee
Klinge Pharma GmbH and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Klinge Pharma GmbH and Co filed Critical Klinge Pharma GmbH and Co
Application granted granted Critical
Publication of ES2064130T3 publication Critical patent/ES2064130T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A61K31/025—Halogenated hydrocarbons carbocyclic
    • A61K31/03—Halogenated hydrocarbons carbocyclic aromatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

REMEDIOS PARA ENFERMEDADES OSEAS QUE COMPRENDEN, COMO INGREDIENTE ACTIVO, DROLOXIFENO O UNA SAL DEL MISMO.
ES92105595T 1991-04-09 1992-04-01 Utilizacion de droloxifeno para el tratamiento de enfermedades de los huesos. Expired - Lifetime ES2064130T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP3166944A JPH04312526A (ja) 1991-04-09 1991-04-09 骨疾患治療剤

Publications (1)

Publication Number Publication Date
ES2064130T3 true ES2064130T3 (es) 1995-01-16

Family

ID=15840531

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92105595T Expired - Lifetime ES2064130T3 (es) 1991-04-09 1992-04-01 Utilizacion de droloxifeno para el tratamiento de enfermedades de los huesos.

Country Status (14)

Country Link
US (1) US5254594A (es)
EP (1) EP0509317B1 (es)
JP (1) JPH04312526A (es)
KR (1) KR100196810B1 (es)
AT (1) ATE114113T1 (es)
AU (1) AU648154B2 (es)
CA (1) CA2065093C (es)
DE (1) DE69200675T2 (es)
DK (1) DK0509317T3 (es)
EE (1) EE02971B1 (es)
ES (1) ES2064130T3 (es)
HK (1) HK1004257A1 (es)
IE (1) IE66900B1 (es)
ZA (1) ZA922527B (es)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5811447A (en) * 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6306421B1 (en) 1992-09-25 2001-10-23 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6251920B1 (en) 1993-05-13 2001-06-26 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US5770609A (en) * 1993-01-28 1998-06-23 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6395494B1 (en) 1993-05-13 2002-05-28 Neorx Corporation Method to determine TGF-β
AU5286693A (en) 1992-10-27 1994-05-24 Nippon Kayaku Kabushiki Kaisha Use of non steroidal anti estrogens for autoimmune diseases
US5886049A (en) * 1992-10-27 1999-03-23 Nippon Kayaku Kabushiki Kaisha Remedy for autoimmune diseases
US5595722A (en) * 1993-01-28 1997-01-21 Neorx Corporation Method for identifying an agent which increases TGF-beta levels
US5981568A (en) * 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6663881B2 (en) * 1993-01-28 2003-12-16 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
DE4401554A1 (de) * 1993-02-16 1994-08-18 Freund Andreas Präparat zur Therapie und Prophylaxe von Erkrankungen, die bei Imbalancen von Plasmalipiden auftreten
US5482949A (en) * 1993-03-19 1996-01-09 Eli Lilly And Company Sulfonate derivatives of 3-aroylbenzo[b]thiophenes
DE69435137D1 (de) * 1993-05-13 2008-10-16 Poniard Pharmaceuticals Inc Prävention und behandlung von pathologien, die mit einer abnormalen proliferationglatter muskelzellen verbunden sind
ZA944377B (en) * 1993-06-24 1995-12-20 Lilly Co Eli Hypoglycemic agents
US5384332A (en) * 1994-05-11 1995-01-24 Eli Lilly And Company Methods for inhibiting aortal smooth muscle cell proliferation and restenosis with 1,1,2-triphenylbut-1-ene derivatives
US5426123A (en) * 1994-05-11 1995-06-20 Eli Lilly And Company Method for lowering serum cholesterol with 1,1,2-triphenylbut-1-ene derivatives
US5455275A (en) * 1994-05-11 1995-10-03 Eli Lilly And Company Methods for inhibiting endometriosis and uterine fibroid disease with 1,1,2-triphenylbut-1-ene derivatives
US5441986A (en) * 1994-07-19 1995-08-15 Pfizer Inc. Estrogen agonists as remedies for prostate and cardiovascular diseases
UA41909C2 (uk) 1994-07-22 2001-10-15 Елі Ліллі Енд Компані Використання комбінації сполук для інгібірування остеопорозу, фармацевтичний препарат
US5489587A (en) * 1995-01-20 1996-02-06 Eli Lilly And Company Benzofurans used to inhibit bone loss
CA2223595C (en) 1995-06-07 2008-08-05 Neorx Corporation Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
US5733937A (en) * 1996-02-28 1998-03-31 Pfizer Inc. Methods for alleviating symptoms of premenstrual syndrome and late luteal phase dysphoric disorder
IL120270A0 (en) * 1996-02-28 1997-06-10 Pfizer Combination therapy to treat osteoporosis
US5985932A (en) * 1996-02-28 1999-11-16 Pfizer Inc Inhibition of autoimmune diseases
IL120269A0 (en) * 1996-02-28 1997-06-10 Pfizer 1,1,2-triphenylbut-1-ene derivatives for treating Alzheimer's disease
US5719190A (en) * 1996-02-28 1998-02-17 Pfizer Inc. Inhibition of myeloperoxidase activity
IL120262A (en) * 1996-02-28 2001-01-28 Pfizer Droloxifene and derivatives thereof for use in increasing serum testosterone levels
IL120263A0 (en) * 1996-02-28 1997-06-10 Pfizer Combination therapy to prevent bone loss-progesterone and estrogen agonists
US5726207A (en) * 1996-02-28 1998-03-10 Pfizer Inc. Protection of ischemic myocardium against reperfusion damage
TW442286B (en) * 1996-02-28 2001-06-23 Pfizer New therapeutic uses of estrogen agonists
IL120266A (en) 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
HN1996000101A (es) 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis
US6110942A (en) * 1996-06-17 2000-08-29 Eli Lilly And Company Method for minimizing the uterotrophic effect of droloxifene
CA2207141A1 (en) * 1996-07-15 1998-01-15 David Thompson Berg Benzothiophene compounds, and uses and formulations thereof
US5792798A (en) * 1996-07-29 1998-08-11 Eli Lilly And Company Method for inhibiting plasminogen activator inhibitor 1
US6114395A (en) * 1996-11-15 2000-09-05 Pfizer Inc. Method of treating atherosclerosis
US6034102A (en) * 1996-11-15 2000-03-07 Pfizer Inc Atherosclerosis treatment
US6069175A (en) * 1996-11-15 2000-05-30 Pfizer Inc. Estrogen agonist/antagonists treatment of atherosclerosis
US6117911A (en) * 1997-04-11 2000-09-12 Neorx Corporation Compounds and therapies for the prevention of vascular and non-vascular pathologies
EP0897720A1 (en) * 1997-08-13 1999-02-24 Pfizer Products Inc. Droloxifene for prevention of breast cancer
US6077871A (en) * 1997-11-26 2000-06-20 Pfizer Inc. Droloxifene pharmaceutical compositions
EP1253966B1 (de) * 1999-08-13 2011-04-27 Curadis GmbH Substanzen und mittel zur positiven beeinflussung von kollagen
US20060105992A1 (en) * 2004-11-08 2006-05-18 Buchanan Charles M Pharmaceutical formulations of cyclodextrins and selective estrogen receptor modulator compounds
WO2006052921A2 (en) * 2004-11-08 2006-05-18 Eastman Chemical Company Cyclodextrin solubilizers for liquid and semi-solid formulations
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US20090143343A1 (en) * 2007-11-13 2009-06-04 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract
SI3354276T1 (sl) 2007-11-13 2020-09-30 Meritage Pharma, Inc. Sestavki za zdravljenje gastrointestinalnega vnetja
US20100216754A1 (en) * 2007-11-13 2010-08-26 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4206234A (en) * 1977-08-22 1980-06-03 Imperial Chemical Industries Limited Triphenylbut-1-ene derivatives and pharmaceutical compositions and uses thereof
EP0002097B1 (en) * 1977-08-22 1981-08-05 Imperial Chemical Industries Plc Triphenylalkene derivatives, process for their preparation and pharmaceutical compositions containing them
DE3046719C2 (de) * 1980-12-11 1983-02-17 Klinge Pharma GmbH, 8000 München 1,1,2-Triphenyl-but-1-en-Derivate, Verfahren zu ihrer Herstellung und Arzneimittel
US4729999A (en) * 1984-10-12 1988-03-08 Bcm Technologies Antiestrogen therapy for symptoms of estrogen deficiency

Also Published As

Publication number Publication date
EE02971B1 (et) 1997-04-15
KR920019342A (ko) 1992-11-19
HK1004257A1 (en) 1998-11-20
ZA922527B (en) 1992-12-30
AU648154B2 (en) 1994-04-14
US5254594A (en) 1993-10-19
EP0509317B1 (en) 1994-11-17
DK0509317T3 (da) 1995-01-30
AU1399492A (en) 1992-10-15
JPH04312526A (ja) 1992-11-04
ATE114113T1 (de) 1994-12-15
EP0509317A2 (en) 1992-10-21
DE69200675D1 (de) 1994-12-22
DE69200675T2 (de) 1995-03-16
IE66900B1 (en) 1996-02-07
CA2065093C (en) 1995-10-03
EP0509317A3 (en) 1993-03-03
KR100196810B1 (ko) 1999-06-15
IE921116A1 (en) 1992-10-21
CA2065093A1 (en) 1992-10-10

Similar Documents

Publication Publication Date Title
ES2064130T3 (es) Utilizacion de droloxifeno para el tratamiento de enfermedades de los huesos.
MX9304432A (es) Compuestos y formulaciones farmaceuticas para el tratamiento o prevencion de la osteoporosis y la perdida de los huesos.
DE3382458D1 (de) Haarwuchsmittel.
ES2164111T3 (es) Empleo del principio activo flupirtina para la preparacion de un medicamento para combatir espasmos musculares.
ES278010Y (es) Clavo oseo, especialmente clavo de boqueo, para el tratamiento de fracturas de hueso
ES2063033T3 (es) Empleo de igf-ii en el tratamiento de la enfermedades de los huesos.
EP0444196A4 (en) Agent for treatment and prophylaxis of ischemic disease of heart or brain
ES2083597T3 (es) Preparacion farmaceutica para el tratamiento del tiempo de coagulacion prolongado.
ES2109752T3 (es) Medicamento para tratamiento terapeutico y profilactico de enfermedades causadas por hiperplasia de las celulas de los musculos lisos.
ES2177024T3 (es) Empleo de la fanquinoma para el tratamiento de la enfermedaad de alzheimer.
DK0750616T3 (da) Syreadditionssalte af 2,3,4,5-tetrahydro-1H-3-benzazapinforbindelser
ES2135500T3 (es) Producto farmaceutico para el tratamiento de trastornos de la piel.
GR3032224T3 (en) Therapeutic agent for threatened abortion.
GT199900083A (es) Combinaciones terapeuticas para la fragilidad musculoesqueletica.
MX9204286A (es) Agentes para el tratamiento de semillas.
DK664188D0 (da) Butylhydroxyanisoler til behandling af retrovirale sygdomme
ES2190499T3 (es) Uso de antagonistas de bradiquinina para la preparacion de medicamentos para el tratamiento y la prevencion de la enfermedad de alzheimer.
DK0493861T3 (da) Antidepressivt præparat indeholdende nikotinamid-adenin-dinukleotid
MX9203362A (es) Composicion diuretica de benazepril/tiazida de dosis baja, para el tratamiento de la hipertension
ES1004491Y (es) Horma para el tratamiento ortopedico de calzado.
ES291814Y (es) Protesis perfeccionada de osteosintesis para el tratamiento de las fracturas del femur
ES1032126Y (es) Juego esterilizable para la autoinyeccion de drogas.
GR3037039T3 (en) Use of trimetazidine for the preparation of medicaments for the treatment of troubles due to the therapeutical use of immunosuppressants.
ES1008313Y (es) Clavo intramedular para el tratamiento de fracturas de huesos largos.
MX9203715A (es) Preparciones para el tratamiento del tejido aloinjertado.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 509317

Country of ref document: ES